Home › Compare › TNPOF vs ABBV
TNPOF yields 13.97% · ABBV yields 3.09%● Live data
📍 TNPOF pulled ahead of the other in Year 1
Combined, TNPOF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TNPOF + ABBV for your $10,000?
Ten Pao Group Holdings Limited, an investment holding company, develops, manufactures, and sells electric charging products in the People's Republic of China, the rest of Asia, the United States, Europe, Africa, and internationally. It operates through six segments: Telecommunication, Media and Entertainment, Electrical Home Appliances, Lighting, Smart Chargers and Controllers, and Others. The company offers switching power supply units, such as quick chargers, wireless chargers, and adapters; LED power supply products; electric vehicle chargers; switched-mode power supply units; power tools; power inverters; and other power supply solutions for clients in the security, industrial automation and control system, machinery, electrical equipment, and communication applications. It is also involved in trading audio devices, substation cabinets, and power supply devices and raw materials. In addition, the company provides building decoration services. Ten Pao Group Holdings Limited was founded in 1979 and is headquartered in Kwun Tong, Hong Kong.
Full TNPOF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.